Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
NICORETTE is a nicotine polacrilex chewing gum approved in 1992 for smoking cessation as an over-the-counter nicotine replacement therapy. It works as a cholinergic nicotinic agonist, delivering nicotine through the buccal mucosa to reduce cravings and withdrawal symptoms in patients quitting tobacco. The product remains a foundational OTC aid for smokers attempting to quit.
With LOE approaching in 2028 and 15 competitors in a saturated market, this mature OTC brand faces declining team investment and consolidation pressures typical of post-patent-expiry products.
Cholinergic Nicotinic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers
"EASY EFFECTIVE SMOKELESS" With NICORETTE®
Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum
Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment
Worked on NICORETTE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
NICORETTE offers limited career growth opportunities due to its mature LOE-approaching status and commodity-like competitive position. Roles on this team tend to focus on defensive margin management, cost optimization, and transition planning rather than innovation or expansion.